Eli Lilly and Company

Robust preclinical pipeline of non-hallucinogenic neuroplastogens designed as potential best-in-class treatments for neuropsychiatric and neurodegenerative...

Some experts say oral versions of popular weight-loss drugs such as Wegovy could offer people more flexibility and accessibility. What's keeping the pills from taking off?

Adding surgery maintained remission better than medical therapy alone

Eli Lilly's experimental pill worked as well as blockbuster drug Ozempic to lower weight and blood sugar in a trial of diabetes patients, and the company said it expects to...

Promising late-stage trial results lift US pharmaceutical group's shares

Swedish study suggests more MACE with delayed addition of ezetimibe to statins after heart attack

The U.S. Food and Drug Administration on Monday warned consumers and pharmacies that fake versions of Ozempic, a drug to treat Type 2 diabetes, have been found in the United States.

The company announced it's ending development of its oral drug danuglipron after a liver injury to a patient

Better targeting, optimization, earlier treatment create potential for increased use

Programmable RNA sensor and molecular tools refine therapeutic payload production

The pharma giants shared new clinical trial results, highlighting potential heart benefits of their meds

Eli Lilly is escalating its legal push to protect the exclusivity of its high-profile weight-loss and diabetes drugs, Zepbound and Mounjaro, by suing two compounding pharmacies — Strive Pharmacy and Empower Pharmacy — over their continued production of altered tirzepatide formulations. Filed on Tuesday in Delaware and New Jersey, the lawsuits mark Lilly's first legal […]

Donald Trump doesn't rule out seeking a third term.

Republicans are privately grumbling about President Trump's economy as fears of a recession and turmoil on Wall Street overshadow manufacturing job gains and cooling inflation.

Health news and commentary gathered by MedPage Today staff

Makers of the popular obesity treatments Wegovy and Zepbound are cutting prices for people without insurance

The pharmacy, called NovoCare, will allow patients to pay $499 in cash per month for the blockbuster weight loss drug.

The pharma company announced has launched two late-stage trials of its monthly weight loss drug

Thousands of patients with lung cancer face delays in genomic testing, preventing timely access to targeted treatments that could improve survival rates, according to a report.